Reinstated p53 response and high anti-T-cell leukemia activity by the novel alkylating deacetylase inhibitor tinostamustine

Leukemia. 2020 Sep;34(9):2513-2518. doi: 10.1038/s41375-020-0772-6. Epub 2020 Feb 25.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Alkylating / pharmacology*
  • Apoptosis / drug effects
  • Benzimidazoles / pharmacology*
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Leukemia, T-Cell / genetics
  • Leukemia, T-Cell / pathology*
  • Mutation
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism*

Substances

  • Antineoplastic Agents, Alkylating
  • Benzimidazoles
  • Histone Deacetylase Inhibitors
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • tinostamustine